The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study

Dear Study Team,

I am a patient in China and I am interested in participating in your clinical trial:

Study Title: The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
ClinicalTrials.gov Identifier: NCT04513639
Sponsor: Oslo University Hospital
Investigational product: Early treatment of relapse with carfilzomib, dexamethasone, daratumumab, Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab

About me:
- Age: (please fill in)
- Sex: (please fill in)
- Confirmed diagnosis and stage: (please fill in)
- Biomarkers / genetic testing: not available
- Prior and current treatments: (please fill in)
- Performance status (ECOG): not assessed
- Current location: China
- Travel ability: (please fill in)

Could you please let me know:
1. Whether I might be eligible for this study;
2. Which site would be closest and most practical for me, and whether remote pre-screening is possible;
3. What documents (medical records, pathology or imaging reports, recent labs) I should prepare for pre-screening.

I can provide English translations of my medical records. Thank you very much for your time and help.

Kind regards,
(your name)
(your email / phone with country code)

尊敬的研究团队：

我是一位来自中国的患者，希望咨询参加以下临床试验的可能：

研究名称：The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
试验编号：NCT04513639
申办方：Oslo University Hospital
研究药物：Early treatment of relapse with carfilzomib, dexamethasone, daratumumab、Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab

我的基本情况：
- 年龄：（请填写）
- 性别：（请填写）
- 确诊疾病与分期：（请填写）
- 基因／标志物检测：暂无
- 既往及当前治疗：（请填写）
- 体能状态（ECOG）：未评估
- 目前所在城市：中国
- 可前往范围：（请填写）

想请教三个问题：
1. 我是否可能符合本研究的入组标准？
2. 哪个中心对我最方便可行？能否远程预筛？
3. 预筛需要准备哪些资料（病历、病理、影像、近期化验）？

我可以提供英文翻译版病历。感谢您的时间与帮助。

顺祝安康
（您的姓名）
（您的邮箱／带国际区号的电话）